Abstract:Background: Genomic instability of N6-methyladenosine (m 6 A)–related long noncoding RNAs (lncRNAs) plays a pivotal role in the tumorigenesis of lung adenocarcinoma (LUAD). Our study identified a signature of genomic instability of m 6 A-associated lncRNA signature and revealed its prognostic role in LUAD. Methods: We downloaded RNA-sequencing data and somatic mutation data for LUAD from The Cancer Genome Atlas (TCGA) and the GSE102287 dataset from the Gene Expression Omnibus (GEO) database. The “Limma” R package was used to identify a network of regulatory m 6 A-related lncRNAs. We used the Wilcoxon test method to identify genomic-instability–derived m 6 A-related lncRNAs. A competing endogenous RNA (ceRNA) network was constructed to identify the mechanism of the genomic instability of m 6 A-related lncRNAs. Univariate and multivariate Cox regression analyses were performed to construct a prognostic model for internal testing and validation of the prognostic m 6 A-related lncRNAs using the GEO dataset. Performance analysis was conducted to compare our prognostic model with the previously published lncRNA models. The CIBERSORT algorithm was used to explore the relationship of m 6 A-related lncRNAs and the immune microenvironment. Prognostic m 6 A-related lncRNAs in prognosis, the tumor microenvironment, stemness scores, and anticancer drug sensitivity were analyzed to explore the role of prognostic m 6 A-related lncRNAs in LUAD. Results: A total of 42 genomic instability–derived m 6 A-related lncRNAs were differentially expressed between the GS (genomic stable) and GU (genomic unstable) groups of LUAD patients. Four differentially expressed lncRNAs, 17 differentially expressed microRNAs, and 75 differentially expressed mRNAs were involved in the genomic-instability–derived m 6 A-related lncRNA-mediated ceRNA network. A prediction model based on 17 prognostic m 6 A-associated lncRNAs was constructed based on three TCGA datasets (all, training, and testing) and validated in the GSE102287 dataset. Performance comparison analysis showed that our prediction model (area under the curve [AUC] = 0.746) could better predict the survival of LUAD patients than the previously published lncRNA models (AUC = 0.577, AUC = 0.681). Prognostic m 6 A-related-lncRNAs have pivotal roles in the tumor microenvironment, stemness scores, and anticancer drug sensitivity of LUAD. Conclusion: A signature of genomic instability of m 6 A-associated lncRNAs to predict the survival of LUAD patients was validated. The prognostic, immune microenvironment and anticancer drug sensitivity analysis shed new light on the potential novel therapeutic targets in LUAD.

Six-long Non-coding RNA Signature to Predict the Prognosis of Lung Adenocarcinoma

Identification and Validation of a Novel Six-lncRNA-Based Prognostic Model for Lung Adenocarcinoma

Development of a Novel Prognostic Signature of Long Non-Coding RNAs in Lung Adenocarcinoma

A Five-Long Non-Coding RNA Signature with the Ability to Predict Overall Survival of Patients with Lung Adenocarcinoma.

A Novel Neutrophil Extracellular Traps-Related Lncrna Signature Predicts Prognosis in Patients with Early-Stage Lung Adenocarcinoma

LncRNA Expression Signature in Prediction of the Prognosis of Lung Adenocarcinoma.

Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma

Identification of a Universal 6‐lncrna Prognostic Signature for Three Pathologic Subtypes of Renal Cell Carcinoma

Identification of a Novel Prognostic Signature of Genome Instability-Related LncRNAs in Early Stage Lung Adenocarcinoma

Identification of an Immune-related Seven-lncRNA Signature Predicting Prognosis and Tumor-infiltrating Immune Cells in Lung Adenocarcinoma

Expression Analysis of Lncrna As Prognostic Biomarkers in Colon Adenocarcinoma

Identification of Cerna Network Based on a RNA-seq Shows Prognostic Lncrna Biomarkers in Human Lung Adenocarcinoma

Prognostic Value of Genomic Instability of m6A-Related lncRNAs in Lung Adenocarcinoma

A Novel Seven-Long Non-Coding RNA Signature Predicts Survival in Early Stage Lung Adenocarcinoma

A Group of Long Noncoding RNAs Identified by Data Mining Can Predict the Prognosis of Lung Adenocarcinoma

Unique Metastasis‐associated Lncrna Signature Optimizes Prediction of Tumor Relapse in Lung Adenocarcinoma

Establishment of a Lymph Node Metastasis-Associated Prognostic Signature for Lung Adenocarcinoma

Identification of a RNA-Seq based prognostic signature with five lncRNAs for lung squamous cell carcinoma.

Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma

Identification Ofprognostic Indicator Based on Hypoxia-Related Lncrnas Analysis in Lung Adenocarcinoma

A 7-Lncrna Signature Associated with the Prognosis of Colon Adenocarcinoma